Tetramethylpyrazine Nitrone (TBN) Reduces Amyloid β Deposition in Alzheimer's Disease Models by Modulating APP Expression, BACE1 Activity, and Autophagy Pathways

被引:0
|
作者
Zhou, Xinhua [1 ]
Zhu, Zeyu [2 ]
Kuang, Shaoming [1 ]
Huang, Kaipeng [1 ]
Li, Yueping [1 ]
Wang, Yuqiang [2 ,3 ,4 ]
Chen, Haiyun [5 ]
Hoi, Maggie Pui Man [6 ]
Xu, Benhong [7 ]
Yang, Xifei [7 ]
Zhang, Zaijun [2 ,3 ,4 ]
机构
[1] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou Med Res Inst Infect Dis, Guangzhou 510440, Peoples R China
[2] Jinan Univ, Inst New Drug Res, State Key Lab Bioact Mol & Druggabil Assessment, Guangzhou Key Lab Innovat Chem Drug Res Cardiocere, Guangzhou 511436, Peoples R China
[3] Jinan Univ, Coll Pharm, Guangdong Hong Kong Macau Joint Lab Pharmacodynam, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou 511436, Peoples R China
[4] Jinan Univ, Coll Pharm, Chinese Minist Educ MOE, Int Cooperat Lab Tradit Chinese Med Modernizat & I, Guangzhou 511436, Peoples R China
[5] Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Peoples R China
[6] Univ Macau, Inst Chinse Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China
[7] Shenzhen Ctr Dis Control & Prevent, Key Lab Modern Toxicol Shenzhen, Shenzhen 518055, Peoples R China
基金
中国国家自然科学基金;
关键词
amyloid beta; amyloid precursor protein; microRNA; PROTEIN;
D O I
10.3390/ph17081005
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative disorder associated with age. A wealth of evidence indicates that the amyloid beta (A beta) aggregates result from dyshomeostasis between A beta production and clearance, which plays a pivotal role in the pathogenesis of AD. Consequently, therapies targeting A beta reduction represent a promising strategy for AD intervention. Tetramethylpyrazine nitrone (TBN) is a novel tetramethylpyrazine derivative with potential for the treatment of AD. Previously, we demonstrated that TBN markedly enhanced cognitive functions and decreased the levels of A beta, APP, BACE 1, and hyperphosphorylated tau in 3xTg-AD mice. However, the mechanism by which TBN inhibits A beta deposition is still unclear. In this study, we employed APP/PS1 mice treated with TBN (60 mg/kg, ig, bid) for six months, and N2a/APP695swe cells treated with TBN (300 mu M) to explore the mechanism of TBN in A beta reduction. Our results indicate that TBN significantly alleviated cognitive impairment and reduced A beta deposition in APP/PS1 mice. Further investigation of the underlying mechanisms revealed that TBN decreased the expression of APP and BACE1, activated the AMPK/mTOR/ULK1 autophagy pathway, inhibited the PI3K/AKT/mTOR/ULK1 autophagy pathway, and decreased the phosphorylation levels of JNK and ERK in APP/PS1 mice. Moreover, TBN was found to significantly reduce the mRNA levels of APP and BACE1, as well as those of SP1, CTCF, TGF-beta, and NF-kappa B, transcription factors involved in regulating gene expression. Additionally, TBN was observed to decrease the level of miR-346 and increase the levels of miR-147 and miR-106a in the N2a/APP695swe cells. These findings indicate that TBN may reduce A beta levels likely by reducing APP expression by regulating APP gene transcriptional factors and miRNAs, reducing BACE1 expression, and promoting autophagy activities.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Machine learning models for predicting the activity of AChE and BACE1 dual inhibitors for the treatment of Alzheimer's disease
    Dhamodharan, G.
    Mohan, C. Gopi
    MOLECULAR DIVERSITY, 2022, 26 (03) : 1501 - 1517
  • [32] Machine learning models for predicting the activity of AChE and BACE1 dual inhibitors for the treatment of Alzheimer’s disease
    G. Dhamodharan
    C. Gopi Mohan
    Molecular Diversity, 2022, 26 : 1501 - 1517
  • [33] Astrocytic expression of the Alzheimer's disease β-secretase (BACE1) is stimulus-dependent
    Hartlage-Rübsamen, M
    Zeitschel, U
    Apelt, J
    Gärtner, U
    Franke, H
    Stahl, T
    Günther, A
    Schliebs, R
    Penkowa, M
    Bigl, V
    Rossner, S
    GLIA, 2003, 41 (02) : 169 - 179
  • [34] Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model
    Liang, Huiyu
    Shi, Yusheng
    Kou, Zhewen
    Peng, Yonghua
    Chen, Wenjun
    Li, Xiaowen
    Li, Shuji
    Wang, Ying
    Wang, Fang
    Zhang, Xingmei
    PLOS ONE, 2015, 10 (10):
  • [35] GSK3 signaling regulates BACE1 expression and APP processing and its pharmaceutical potential for Alzheimer's disease
    Song, W.
    Ly, P.
    Wu, Y.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 17 - 17
  • [36] Peripheral Activity and Central Substrates of BACE1: Therapeutic Implications for Alzheimer's Disease
    Ehlers, Michael D.
    BIOLOGICAL PSYCHIATRY, 2018, 83 (05) : 393 - 394
  • [37] A strategy focused on MAPT, APP, NCSTN and BACE1 to build blood classifiers for Alzheimer's disease
    Herrera-Rivero, Marisol
    Elena Hernandez-Aguilar, Maria
    Emiliano Aranda-Abreu, Gonzalo
    JOURNAL OF THEORETICAL BIOLOGY, 2015, 376 : 32 - 38
  • [38] MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1
    Zhu, Hong-Can
    Wang, Li-Mei
    Wang, Miao
    Song, Bo
    Tan, Song
    Teng, Jun-Fang
    Duan, Dong-Xiao
    BRAIN RESEARCH BULLETIN, 2012, 88 (06) : 596 - 601
  • [39] Progress in the development of BACE1 inhibitors as potential anti-amyloid drugs for Alzheimer's disease
    Shitaka, Yoshitsugu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 20P - 20P
  • [40] miRNA-31 Improves Cognition and Abolishes Amyloid-β Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer's Disease
    Barros-Viegas, Ana Teresa
    Carmona, Vitor
    Ferreiro, Elisabete
    Guedes, Joana
    Cardoso, Ana Maria
    Cunha, Pedro
    de Almeida, Luis Pereira
    de Oliveira, Catarina Resende
    de Magalhaes, Joao Pedro
    Peca, Joao
    Cardoso, Ana Luisa
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 19 : 1219 - 1236